Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CD7 Antibodies

The CD7 protein, encoded by the CD7 gene, is a transmembrane glycoprotein primarily expressed on T cells and natural killer (NK) cells. The CD7 gene is on chromosome 17q25 and encodes a protein comprising approximately 240 amino acids, resulting in a molecular weight of around 27 kDa. CD7 undergoes various post-translational modifications, including phosphorylation and glycosylation, which are essential for its function. As a membrane protein, CD7 is crucial in T-cell and NK cell development, activation, and adhesion. It is involved in immune cell signaling and interactions with other immune cells and antigen-presenting cells. CD7 expression is observed in various lymphoid tissues, such as the thymus, spleen, and lymph nodes, as well as in circulating T cells and NK cells. The expression of CD7 is regulated during lymphocyte development and activation, influenced by various factors, including cytokines and antigen stimulation. 

CD7 expression has diagnostic and prognostic value in certain diseases, particularly hematologic malignancies. In the context of T-cell acute lymphoblastic leukemia (T-ALL), CD7 expression is commonly used as a diagnostic marker. The presence of CD7 on leukemic blasts helps distinguish T-ALL from other types of leukemia, aiding in accurate disease classification and treatment planning. Additionally, CD7 expression levels may provide prognostic information in T-ALL, with higher CD7 expression associated with more aggressive disease and poorer treatment outcomes. In other hematologic malignancies, such as T-cell lymphomas, CD7 expression may also serve as a diagnostic marker and contribute to disease stratification. However, the prognostic significance of CD7 expression in these diseases may vary depending on various factors, including disease subtype and treatment response.

A recent study reported about an anti-CD7 antibody-drug conjugate (ADC) named J87-Dxd for T-ALL treatment. In vitro assays demonstrated significant antitumor activity. In vivo studies using T-ALL mouse models showed an 80% survival rate. Thus, targeting CD7 may be a promising therapeutic approach for T-ALL and other CD7-expressing tumors.

NeoBiotechnologies offers a variety of antibodies against CD7 that have been validated for flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting. Additionally, we hold exclusive rights to CD7 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/gene-name/cd7/].


T-cell antigen CD7, GP40, T-cell leukemia antigen, T-cell surface antigen Leu-9, TP41, GP40; Leu9; p41; T-cell leukemia antigen; T-cell surface antigen Leu-9; Tp40; TP41

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lung Cancer, MAPK Signaling, Mast Cell Marker, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors

Showing all 14 results


Showing all 14 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.